Indeed, developing therapeutics also for the modulation of alternative targets, and not only devoted to CFTR rescue, could be essential for CF patients expressing undruggable CFTR mutants and could also be useful as an adjuvant therapy supporting the effect of CFTR modulators. This evidence concerns the gene CFTR and cystic fibrosis.